Immunogenicity and safety assessments of MMR vaccine with new mumpes component (RS12)

Phase 2

• Conditions: Condition 1: Measles. Condition 2: rubella. Condition 3: Mumps.; viral infections characterized by skin and mucous membraine lesions; Other viral diseases

• Registration Number: IRCT201206304412N6
• Lead Sponsor: Razi Vaccine & Serum Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 420

Inclusion Criteria

in 12 – 24 months old children
Negative history of any exposure to measeles , rubella and mumps in the the preceding 4 weeks ; Negative history of previous MMR immunization ; Negative history of immunosuppressive therapy; Negative history of previous infection by measeles , rubella and mumps viruses ; obtaining written informed consent ; Negative history of radiotherapy;
Exclusion criteria : in 12 – 24 months old children
Positive history of autoimmune disorders , genetic and congenital disease; Positive history of kidney and liver disease; fever of >38.cc at time of assessment; Positive history of other signs of acute infections; Positive history of administration immunoglobins or blood transfusions within the previous three months; Positive history of allergy to any vaccine components; Positive history of prematurity ,mental retardation ; Positive history of convulsion or any neurological disorder;

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified